A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Christian Sonia; Kozma Kelley E.; Barath Stephanie; Shergill Ardaman; Rondelli Damiano; Peace David; Saraf Santosh L.; Oh Annie Lee; Sweiss Karen; Khan Irum; Patel Pritesh; Dudek Arkadiusz; Quigley John G.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

【24h】

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

机译：在新诊断的AML患者中添加奥替己酸盐与含糖量和近霉素的标准诱导方案的安全性研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
作者
Christian Sonia; Kozma Kelley E.; Barath Stephanie; Shergill Ardaman; Rondelli Damiano; Peace David; Saraf Santosh L.; Oh Annie Lee; Sweiss Karen; Khan Irum; Patel Pritesh; Dudek Arkadiusz; Quigley John G.;
展开▼
作者单位

Univ Illinois Canc Ctr Chicago IL USA;

St Joseph Hosp Presence Ctr Canc Care Chicago IL USA;

Univ Illinois Canc Ctr Chicago IL USA;

Univ Illinois Canc Ctr Chicago IL USA;

Univ Illinois Canc Ctr Chicago IL USA;

Univ Illinois Coll Med Div Hematol Oncol Chicago IL USA;

Univ Illinois Dept Med Chicago IL USA;

Univ Illinois Canc Ctr Chicago IL USA;

Univ Illinois Canc Ctr Chicago IL USA;

Univ Illinois Chicago IL USA;

Univ Illinois Canc Ctr Chicago IL USA;

Univ Illinois Canc Ctr Chicago IL USA;

Univ Illinois Canc Ctr Chicago IL USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献

1. A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients [J] . Christian Sonia, Kozma Kelley E., Barath Stephanie, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在新诊断的AML患者中添加奥替己酸盐与含糖量和近霉素的标准诱导方案的安全性研究
2. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). [J] . R Willemze, S Suciu, P Muus, Annals of hematology . 2014,第6期

机译：Clofarabine与预先治疗的中间体和坏风险急性髓性白血病（AML）或高风险骨髓增生综合征（HR-MDS）的患者中的标准缓解诱导方案（胞嘧啶阿拉伯苷和含替代素）组合的患者：持续阶段的阶段 E / II研究EORTC和GIMEMA的白血病组（EORTC Gimema 06061 / AML-14A试验）。
3. A comparative study of idarubicin 12 mg/m2 and 8 mg/m2 combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients [J] . Li Zhou, Xin Liu, Huilan Liu, OncoTargets and therapy . 2016,第3期

机译：成年急性髓细胞性白血病首次诱导方案联合阿达比星12 mg / m 2 和8 mg / m 2 联合阿糖胞苷的比较研究
4. The clinical cohort study on prospective efficacy of CHD Therapeutic Regimen of “the regulation of Pi(Spleen) and protection of Xin(Heart)” method treating CHD patients [C] . Danping Xu, Xia Wang, Wenjie Luo, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：“ Pi（脾）的调节和心（心）的保护”法治疗冠心病的冠心病治疗方案前瞻性临床队列研究
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. A comparative study of idarubicin 12 mg/m2 and 8 mg/m2 combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients [O] . Li Zhou, Xin Liu, Huilan Liu, 2016

机译：成年急性髓细胞性白血病患者首次将伊达比星12 mg / m2和8 mg / m2联合阿糖胞苷联合应用的比较研究
7. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial) [O] . Jürgen Krauter, Walter Fiedler, Richard F. Schlenk, 2018

机译：肝脏和紫芽蛋白的I / II类研究结合新诊断患者急性髓性白血病患者氯氟沙滨的升级剂量和诱导症失败风险高（AMLSG 17-10冠军审判）

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

著录项

相似文献

相关主题

期刊订阅